SCHEMBL2178995

SCHEMBL2178995

Cc1ccc(NC(=O)Nc2ccc(-c3ccc4c(c3)C(=O)N([C@H](C(=O)O)C(C)C)C4)cc2F)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
THRB P10828 2/20 0.49
SDCBP O00560 4/20 0.44
SDC2 P34741 4/20 0.44
MAPT P10636 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
KDR P35968 2/20 0.42
TP53 P04637 1/20 0.41
ROCK2 O75116 1/20 0.40
MAP4K4 O95819 1/20 0.40
LCK P06239 1/20 0.40
RET P07949 1/20 0.40
PIM1 P11309 1/20 0.40
RPS6KB1 P23443 1/20 0.40
GSK3B P49841 1/20 0.40
BLK P51451 1/20 0.40
PRKCD Q05655 1/20 0.40
PRKAA1 Q13131 1/20 0.40
STK3 Q13188 1/20 0.40
ROCK1 Q13464 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179002 1.00 LMNA (0.49) LMNATHRBSDCBPSDC2MAPT
SCHEMBL2179912 0.92 LMNA (0.48) LMNATHRBSDCBPSDC2MAPT
SCHEMBL2179818 0.91 LMNA (0.44) LMNATHRBSDCBPSDC2MAPT
SCHEMBL13719256 0.91 LMNA (0.44) LMNATHRBSDCBPSDC2MAPT
SCHEMBL2180144 0.89 NPC1 (0.52) LMNATHRBSDCBPSDC2KDR
SCHEMBL13719149 0.89 NPC1 (0.52) LMNATHRBSDCBPSDC2KDR
SCHEMBL2178484 0.88 LMNA (0.51) LMNATHRBSDCBPSDC2MAPT
SCHEMBL2178978 0.88 LMNA (0.51) LMNATHRBSDCBPSDC2MAPT
SCHEMBL2180486 0.85 LMNA (0.47) LMNATHRBSDCBPSDC2MAPT
SCHEMBL2180326 0.85 LMNA (0.47) LMNATHRBSDCBPSDC2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT LMNA 2193/4885THRB 2612/4885SDCBP 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.